C-RAD AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 44.15 SEK | -0.34% |
|
-9.34% | +4.62% |
| May. 14 | Transcript : C-Rad AB, Q1 2024 Earnings Call, May 14, 2024 | |
| May. 14 | C-Rad AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 53% by 2026.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The group's high margin levels account for strong profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Sales forecast by analysts have been recently revised upwards.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +4.62% | 142M | C | ||
| +8.92% | 222B | B | ||
| +13.65% | 195B | B- | ||
| +23.37% | 148B | B- | ||
| +33.03% | 113B | A- | ||
| +4.18% | 66.45B | A- | ||
| +12.88% | 53.11B | B+ | ||
| +3.16% | 50.03B | B+ | ||
| -4.59% | 38.8B | A | ||
| -2.72% | 34.85B | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- CRAD B Stock
- Ratings C-Rad AB
